Marie-Pier St-Laurent, MD, FRCSC, explains how NeoBLAST combines imaging, TURBT, and ctDNA to identify candidates for bladder-sparing surveillance.
|Videos|August 15, 2022
Dr. Kamran on including immunotherapy in bladder-preservation therapy
Author(s)Urology Times staff
“The NRG SWOG 1806 trial is a phase 3 trial randomizing patients to standard trimodality therapy or trimodality therapy plus atezolizumab,” says Sophia Kamran, MD.
Advertisement
Sophia Kamran, MD, discusses the potential of adding immune-checkpoint inhibitors, such as the PD-L1 inhibitor atezolizumab (Tecentriq) to bladder-preservation, or “trimodal,” therapy for patients with bladder cancer. Kamran is a radiation oncologist at Massachusetts General Hospital and assistant professor of Radiation Oncology at Harvard Medical School.
Advertisement
Related to this article
Mark D. Tyson, II, MD, MPH, reviews emerging bladder-sparing therapies for NMIBC, highlighting cretostimogene data, treatment sequencing, and the need for comparative trials.
This FAQ outlines key recommendations and practical takeaways from the AUA/SUO guideline amendment on the diagnosis and treatment of NMIBC.
Peter Clark, MD, discusses key updates to NMIBC guidelines, including revisions to risk stratification, the emerging role of biomarkers, and how to navigate treatment options for BCG-unresponsive disease.
John P. Sfakianos, MD, discusses how ctDNA can be optimally integrated into bladder cancer clinical trials.
Armine K. Smith, MD, discusses the importance of integrating sexual health into bladder cancer care, including proactive counseling, preservation strategies, and multidisciplinary support.
One year following the approval of the gemcitabine intravesical system, Joseph Jacob, MD, reflects on the expanding treatment landscape in BCG-unresponsive NMIBC.
The PDUFA target action date is in the fourth quarter of 2026.
Advertisement
Advertisement